By Dorothy Leone-Glasser

Breast cancer survivors face many challenges while going through treatment and in post treatment.  They experience a wide range of physical, mental, emotional and spiritual pain. There are lingering side effects to treatment that are long term and can be hard to manage. Many times, the fear of what will happen is overwhelming.  Cancer survivors live with fearing a recurrence, especially with Stage 4 Cancer. This is especially real for women of color, since they have the highest recurrence rates and the highest mortality rates.  

I met Tiah at an Rx in Reach GA Coalition Capitol Day. Being a survivor of Cancer myself, we knew women we would have a special bond. When we look at the journey of a woman living and thriving beyond cancer, oftentimes they don’t get a chance to take a break from the day-to-day challenges of life.  These women are mothers, daughters, sisters and aunties, caregivers and pillars of their families. They are leaders in their community and on their jobs and so much more. One of the biggest needs is how to manage or cope with their daily life challenges while healing from the devastation of cancer and the damaging toll of treatment. Patients seldom receive the information and counseling on how to re-enter life. Cancer survivors and their families and friends need the education, resources and guidance from a healthcare team that supports the health of their mind and body.

Here are some ‘Tips’ from Tiah:

  • SEE ME AS A PERSON BEFORE SEEING ME AS A PATIENT. We are more than our disease.  We have families, friends, jobs, hobbies, goals and dreams.  When you are treating me as a patient, remember – I am not a “one size fits all”. I am uniquely me!  Take time to learn a little bit more about me and what could potentially be barriers to my care.   
  • BE PATIENT WITH ME. What you see on the outside is not always a reflection of what’s going on the inside.  As a patient, I may not always verbalize how I truly feel or the problems I face.  Many patients don’t want to be seen as a burden so we just keep our superhero capes on and press our way through.
  • CANCER IS COMPLICATED. SOMETIMES WE AREN’T GIVEN THE PROPER DIAGNOSIS OR ARE MISDIAGNOSED. Because I look healthy or are very young doesn’t mean I am not seriously ill. I know when something is wrong with my body. I need a care team that hears me.  
  • SOME DAYS I JUST DON’T HAVE THE STRENGTH TO ADVOCATE FOR MYSELF.   This is why having a caregiver/advoacte is so important. 
  • LIVING WITH A CHRONIC ILLNESS CAN BE VERY EMOTIONAL . Cancer comes with the challenges of side effects of treatments and drugs, isolation, fear and anxiety of disease progression or recurrence; all causing a rough ride on an emotional rollercoaster.
Tiah Tomlin headshot
Tiah Tomlin
Founder & CEO,
My Style Matters

Dorothy Leone Glasser headshotDorothy Leon Glasser
Executive Director, Advocates for Responsible Care
Co-Chair, Georgia Bio Patient Advocacy Alliance

Georgia Life Sciences Designates City of Atlanta as Newest BioReady® Community

By Sheran Brown • February 21, 2025
Georgia Life Sciences Designates City of Atlanta as Newest BioReady® Community

Bipartisan PBM Reform Back in Focus as House Committee Plans Hearing

By Sheran Brown • February 20, 2025
A renewed push for prescription drug cost reform is gaining momentum in Congress, with the House Energy and Commerce Committee's health subcommittee planning a hearing on pharmacy benefit manager (PBM) reform for late February. The hearing, to be led by Rep. Buddy Carter (R-Ga.), signals a revival of bipartisan efforts to regulate these pharmaceutical intermediaries. PBMs, which negotiate drug prices for insurers and employers, have become a focal point in the broader discussion of healthcare costs. A previous bipartisan agreement to regulate these entities was crafted by Carter and Rep. Diana DeGette (D-Colo.) in the last Congress, though it ultimately stalled when the larger spending bill it was attached to faced opposition. The reform efforts enjoy broad support from both parties and the president, making it one of the few areas with potential for bipartisan cooperation. However, new complications have emerged as Republicans consider using PBM regulations to generate savings for their broader policy agenda, potentially requiring up to $880 billion in cost reductions. The path forward remains uncertain, with ongoing debates about whether such reforms would qualify for budget reconciliation and whether using PBM regulations as a funding mechanism could derail bipartisan cooperation. Meanwhile, stakeholders continue to disagree on the impact of additional PBM regulation, with pharmaceutical companies arguing that PBMs inflate drug costs while PBMs contend that new regulations would increase prices.

Council on State Biotechnology Associations says NIH funds are a critical component of innovation ecosystem

By Sheran Brown • February 20, 2025
The Council of State Biotechnology Associations (CSBA) has issued a strong warning about proposed cuts to National Institutes of Health (NIH) funding, emphasizing the critical role these grants play in America's biotech innovation ecosystem. The statement, below , comes amid concerns over recent guidance that would reduce NIH funding to key research institutions. ----------------------- “Today, the US biotech industry employs nearly 2.3 million people across the US and is making positive contributions to economic impact and national security across all 50 states. In fact, for every dollar the National Institutes of Health (NIH) contributes to a successful drug, the private sector invests over $65, underscoring the agency’s unparalleled return on investment. As the associations representing the bioscience industry across the nation, the Council on State Biotechnology Associations (CSBA) is concerned by recent guidance that would cut funding provided by the NIH to universities, hospitals, and other institutions that perform critical early-stage research. NIH grant funds are a critical component of our innovation ecosystem. Grants for basic research are the spark that leads to university-driven discoveries, with public-private partnerships and tech transfers that bridge early-stage research to industry-sponsored drug development and ultimately to FDA approved medical advances for hundreds of diseases. While the administration looks for greater efficiency in the use of taxpayer dollars, it cannot be overstated - once scientific innovation moves abroad, it may never return. In the race for scientific innovation around the world, as our adversaries continue to increase government investments in research, we encourage President Trump to follow suit and ensure that we maintain our global leadership in an industry that was created and thrives across the US.”
MORE POSTS
Share by: